Bristol Myers Squibb has announced an agreement with the U.S. government to provide Eliquis (apixaban), the nation’s most prescribed oral blood thinner, free of charge to the Medicaid program. As part of the agreement, the company will donate more than seven tons of Eliquis active pharmaceutical ingredient $(API)$ to support the American supply chain. The agreement also provides Bristol Myers Squibb with three years of tariff relief and exempts the company from future pricing mandates. The specific terms of the agreement remain confidential.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251219775505) on December 19, 2025, and is solely responsible for the information contained therein.
Comments